Now is our last chance to get our voice heard in consultations prior to the 2018 Federal budget. Support the full implementation of the Naylor report. Visit SupportTheReport.ca to see ways to get involved.
Multiple Sclerosis is known as a progressive disease in which symptoms worsen over time. But for some 85% of those who suffer, the first stages of the illness come in waves. The individual may feel perfectly well some days while others are marked with worsening or new symptoms.
Officially this condition is known as relapsing remitting multiple sclerosis (MS) and it is the focus of a large Canadian conglomerate known as the CIHR Team in Epidemiology and Impact of Comorbidity on Multiple Sclerosis, or ECoMS. As the name implies, the group aims to determine how co-existing chronic diseases – comorbidities – affect those suffering with MS. Last week, representatives of the team, headed by Dr. Ruth Ann Marrie at the University of Manitoba and Director of Manitoba’s MS Clinic at Health Sciences Centre Winnipeg, revealed their findings in the journal, Neurology.
Nerve injuries and neurodegenerative diseases such as Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, Multiple Sclerosis (MS) and glaucoma share some characteristics, one of which is the degeneration of a part of neurons called the axon. Axons are long extensions that branch out of the cell body to allow neurons to connect to other cells, including other neurons, to transmit signals. A team led by SickKids scientist David Kaplan with Freda Miller and their trainees Konstantin Feinberg and Adelaida Kolaj has recently identified a drug, called fortetinib, that protects axons from degeneration in multiple conditions. It may turn out to be a clinically useful therapeutic drug.
Injury of the spinal cord is a traumatic and life-changing event that affects over three million people worldwide. Over the last decade, researchers have been examining ways to help repair injured individuals through the use of stem cell transplantation. Significant progress has been made in this area yet many unanswered questions remain. For the laboratory of Dr. Wolfram Tetzlaff at the University of British Columbia, these gaps need to be filled to ensure successful treatments in the future.
A discovery by Hideto Takahashi and his team paves the way for a better understanding of the mechanisms of neuropsychiatric disorders.
Did you know? Your body is made up of a hundred billion nerve cells that, like small computers, receive, process and deliver crucial information to your body. These machines are your neurons. They form the very foundation of your nervous system. It is through them that your brain converts the data transmitted by your retina into images and that your mood adapts to the situations you are living.
Volume in brain region linked to physiological changes characteristic of AD
New research has drawn a link between changes in the brain’s anatomy and biomarkers that are known to appear at the earliest stages of Alzheimer’s disease (AD), findings that could one day provide a sensitive but non-invasive test for AD before cognitive symptoms appear.
A recent publication by Caroline Ménard shows that chronic stress, as occurs in cases of bullying, can make the blood-brain barrier more permeable to contaminants and microbes that may be in the blood. As the brains of depressed individuals show signs of inflammation, Caroline Ménard and her colleagues had hypothesized that leakiness of the blood brain barrier could allow molecules and microbes to reach the brain, causing inflammation.
Learning and memory are crucial parts of human cognition, yet the biological processes that govern how we learn and store different types of memories are poorly understood. Although a cellular process called synaptic plasticity has long been thought to contribute to learning and memory, many of the neural mechanisms behind synaptic plasticity have remained unclear.
In a recently published study entitled The C-terminal tails of endogenous GluA1 and GluA2 differentially contribute to hippocampal synaptic plasticity and learning, researchers from The Hospital for Sick Children (SickKids) have discovered the precise neuronal mechanisms that can regulate synaptic plasticity to influence distinct forms of memory. We sat down with Dr. Zhengping Jia, a Senior Scientist in the Neurosciences & Mental Health Program at SickKids who led the study, published online in Nature Neuroscience.
Dr. David Park has spent countless hours exploring how deactivating a gene impacts the way a cell handles the very nutrients it needs for its own survival and proper function. To Park and his research team, it’s an essential piece of the puzzle that is Parkinson’s disease.
Parkinson’s affects 10 million people worldwide, causing a degeneration of the body’s nerve cells and a progressive loss of motor control.
Deteriorating memory function is a scary, life changing symptom associated with Alzheimer’s disease (AD) – a neurodegenerative disease exhibited by cognitive declines such as speech, behaviour and thinking processes. Even though it is the most common form of dementia and the prevalence is continuously rising, there is no cure. While there are medications to help with symptoms, the disease ultimately results in mortality.